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ERRATUM
Bye AP, Unsworth AJ, Desborough MJ, et al. Severe platelet dysfunction in
NHL patients receiving ibrutinib is absent in patients receiving
acalabrutinib. Blood Adv. 2017;1(26):2610-2623.
In “Acknowledgments” on page 2621 of the 12 December 2017 issue, funding from British Heart
Foundation grant RG/15/2/31224 was not mentioned. The error has been corrected in the published
article.
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